Noopept vs Cycloprolylglycine (CPG)
Cycloprolylglycine — CPG — is the endogenous cyclic dipeptide that Noopept is metabolised to after oral administration. A substantial portion of Noopept's pharmacological activity is attributable to CPG acting in its own right. This is one of the more interesting parent-metabolite relationships in the research-peptide field: Noopept is a prodrug for an endogenous molecule, giving CPG a distinctive dual identity as both an active metabolite and an endogenous neuromodulator.
At a glance
| Noopept | Cycloprolylglycine | |
|---|---|---|
| Chemical class | Peptidomimetic (proline-dipeptide ester) | Endogenous cyclic dipeptide |
| Structure | N-phenylacetyl-L-prolylglycine ethyl ester | cyclo(L-Pro-L-Gly) |
| Origin | Synthetic (Zakusov Institute, 1990s) | Endogenous — produced by mammalian brain |
| Relationship | Prodrug | Active metabolite of Noopept |
| Route | Oral (clinical use in Russia) | Oral / parenteral (research only) |
| Clinical approval | Approved in Russia (2011) for cognitive indications | None |
| Pharmacology | Parent contributes + metabolite CPG contributes | Direct CPG pharmacology, no metabolite step |
| Evidence tier | B (approved clinical use) | C (research-tool level) |
| UK status | Research chemical | Research chemical |
Which to use
Practical research selection
For research designs where clinical translation matters and the practical evidence base is important, Noopept is the reference compound — the Russian clinical approval, published trials, and long real-world use provide a much deeper evidence base than CPG has on its own.
For research designs where mechanistic isolation matters — probing the CPG-mediated pharmacology directly without the parent-compound hydrolysis step introducing variability — CPG is the cleaner research tool. Direct CPG administration produces a more defined pharmacokinetic picture and avoids the rate-limiting metabolic transformation.
Combining the two in a stack is largely redundant: Noopept already produces CPG-mediated effects via its metabolism, so adding direct CPG to a Noopept protocol mainly shifts the pharmacokinetic time-course rather than the underlying pharmacology.
Pharmacokinetics of the transformation
The parent-to-metabolite hydrolysis pathway
Noopept's chemistry — an N-phenylacetyl-L-prolylglycine ethyl ester — is deliberately designed as a prodrug for CPG. The ethyl-ester and N-phenylacetyl groups provide the oral bioavailability that CPG itself lacks, then hepatic and plasma esterases hydrolyse the modifications rapidly after absorption. Under standard oral-administration conditions, plasma CPG appears within minutes of Noopept dosing and represents a substantial fraction of the compound's downstream cognitive-effect pharmacology.
This parent-to-metabolite pharmacokinetic pathway has research-tool implications. Direct CPG administration produces a defined pharmacokinetic picture with predictable plasma-and-brain exposure profiles. Noopept administration produces a two-phase pharmacokinetic profile — the parent compound contribution (short window) plus the CPG metabolite contribution (extending across the compound's effect window). Research designs that need mechanism-specific characterisation can select which profile matches their research question.
Mechanism-of-action attribution
Which effects come from parent, which from metabolite
The mechanism-of-action attribution between parent Noopept and CPG metabolite is partially resolved by direct-CPG-administration research work. BDNF induction and cognitive-plasticity effects are substantially attributable to the CPG metabolite; some glutamate-system modulation effects appear more attributable to the parent Noopept compound directly.
The anxiolytic-adjacent effects of Noopept administration are attributable primarily to the CPG contribution, consistent with the endogenous cyclic-dipeptide nature of CPG and its physiological role as an endogenous cognitive-mood modulator. This attribution framework is one of the substantial mechanistic contributions of the direct-CPG research work — it provides the mechanistic bridge that explains Noopept's specific cognitive and mood-modulation effects.
For research applications, this attribution framework has implications for research design. Research designs specifically focused on the CPG-mediated cognitive-plasticity angle are better served by direct CPG administration; research designs that need the clinical-translation angle and the practical convenience of oral administration are better served by Noopept.